Additionally, immuno-PET imaging with 89Zr-DFO-pertuzumab selectively quantified to evaluate the HER2 downregulation of 17-DMAG treatment in trastuzumab-resistant JIMT-1 breast cancer models. This evidence concerns the gene ERBB2 and breast carcinoma.